Ignite Creation Date:
2024-05-06 @ 7:42 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06105008
Status:
WITHDRAWN
Last Update Posted:
2024-02-21
First Post:
2023-10-23
Brief Title:
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive HER2-low Locally Advanced or Metastatic Breast Cancer
Sponsor:
RemeGen Co Ltd
Organization:
RemeGen Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12-20
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-12-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04-10
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-23
First Submit QC Date:
October 23 2023
Study First Post Date:
2023-10-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-21
Last Update Post Date:
2024-02-21
Last Update Post Date Type:
ACTUAL